Rhea Raghu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rhea Raghu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Irfan Rahman
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
3 shared publications - Yehao Sun
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, United States
3 shared publications - Eun D. Lee
Department of Microbiology and Immunology, School of Medicine, Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
2 shared publications - Karen Lin
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA
2 shared publications - Parth Suharu
Department of Environmental Medicine, University of Rochester Medical Center, Rochester, NY, United States
2 shared publications Atallah Elzein
UK Health Security Agency, Radiation, Chemical, Climate and Environmental Hazards, Chilton, Didcot, Oxfordshire OX11 ORQ, UK
1 shared publication
Latest Publications
- 31 January 2026
- Published by Elsevier in Toxicology
- Vol. 522, 154421
A comparative toxicological evaluation of nicotine and its analog 6-methyl nicotine in E-cigarette aerosol utilizing a 3D in vitro human respiratory model
- 31 January 2026
- Published by Elsevier in Toxicology
- Vol. 522, 154421
A comparative toxicological evaluation of nicotine and its analog 6-methyl nicotine in E-cigarette aerosol utilizing a 3D in vitro human respiratory model
- Open Access
- 9 January 2026
- Published by Elsevier in Toxicology Reports
- Vol. 16, 102202
Toxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products
- 9 January 2026
- Published by Elsevier in Toxicology Reports
- Vol. 16, 102202
Open AccessToxicity and health effects of delta-8, delta-9, and delta-10-tetrahydrocannabinol and unregulated cannabinoids in vaping products
- Open Access
- 12 September 2025
- Published by MDPI AG in Preprints.org
Health Effects of Delta-8, Delta-9, and Delta-10-Tethydrocannabinol and New Unregulated THC Vaping Products
Hemp-derived cannabinoids (CBDs) such as Δ8- and Δ10-tetrahydrocannabinol (THC) in cannabis e-cigarettes have been growing in popularity among youth, causing a great concern for their health effects. Previous novel lung injury outbreaks, namely E-cigarette or Vaping Use-Associated Lung Injury (EVALI), were associated with the rising use of e-cigarettes and vaping products. Toxicological studies have revealed that chronic exposure to cannabis vapor can cause adverse brain and pulmonary effects. Federal regulatory policies like the United States 2018 Farm Bill classify hemp as cannabis and set a limit of no more than 0.3% Δ9-THC, while products containing more than 0.3% are defined as ‘marijuana.’ This regulatory loophole has led to the proliferation of hemp-derived intoxicating cannabinoids, such as Δ8- and Δ10-THC, in addition to cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG) and Δ9-THC appearing in combination products on the market. This phenomenon poses significant health risks to youth because these newer THC isomers and products are currently unregulated and not well-researched, yet they are still widely available. Therefore, we have examined the potential therapeutical uses, toxicity, pharmacology, and possible health risks of several THC and hemp-derived cannabinoids. This review also draws insightful highlights to the public health consequences of secondary exposures to CBD and THC, and their molecular mechanisms of actions. It underscores the urgency for a strict regulatory oversight over unregulated cannabinoid markets to prevent other vaping-related health crises and other rapidly emerging cannabis health disorders, like the cannabinoid hyperemesis syndrome (CHS).
- 12 September 2025
- Published by MDPI AG in Preprints.org
Open AccessHealth Effects of Delta-8, Delta-9, and Delta-10-Tethydrocannabinol and New Unregulated THC Vaping Products
Hemp-derived cannabinoids (CBDs) such as Δ8- and Δ10-tetrahydrocannabinol (THC) in cannabis e-cigarettes have been growing in popularity among youth, causing a great concern for their health effects. Previous novel lung injury outbreaks, namely E-cigarette or Vaping Use-Associated Lung Injury (EVALI), were associated with the rising use of e-cigarettes and vaping products. Toxicological studies have revealed that chronic exposure to cannabis vapor can cause adverse brain and pulmonary effects. Federal regulatory policies like the United States 2018 Farm Bill classify hemp as cannabis and set a limit of no more than 0.3% Δ9-THC, while products containing more than 0.3% are defined as ‘marijuana.’ This regulatory loophole has led to the proliferation of hemp-derived intoxicating cannabinoids, such as Δ8- and Δ10-THC, in addition to cannabidiol (CBD), cannabinol (CBN), cannabigerol (CBG) and Δ9-THC appearing in combination products on the market. This phenomenon poses significant health risks to youth because these newer THC isomers and products are currently unregulated and not well-researched, yet they are still widely available. Therefore, we have examined the potential therapeutical uses, toxicity, pharmacology, and possible health risks of several THC and hemp-derived cannabinoids. This review also draws insightful highlights to the public health consequences of secondary exposures to CBD and THC, and their molecular mechanisms of actions. It underscores the urgency for a strict regulatory oversight over unregulated cannabinoid markets to prevent other vaping-related health crises and other rapidly emerging cannabis health disorders, like the cannabinoid hyperemesis syndrome (CHS).
- Open Access
- 10 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8585
Overexpression of ERAP2N in Human Trophoblast Cells Promotes Cell Death
The genes involved in implantation and placentation are tightly regulated to ensure a healthy pregnancy. The endoplasmic reticulum aminopeptidase 2 (ERAP2) gene is associated with preeclampsia (PE). Our studies have determined that an isoform of ERAP2-arginine (N), expressed in trophoblast cells (TC), significantly activates immune cells, and ERAP2N-expressing TCs are preferentially killed by both cytotoxic T lymphocytes (CTLs) and Natural Killer cells (NKCs). To understand the cause of this phenomenon, we surveyed differentially expressed genes (DEGs) between ERAP2N expressing and non-expressing TCs. Our RNAseq data revealed 581 total DEGs between the two groups. 289 genes were up-regulated, and 292 genes were down-regulated. Interestingly, most of the down-regulated genes of significance were pro-survival genes that play a crucial role in cell survival (LDHA, EGLN1, HLA-C, ITGB5, WNT7A, FN1). However, the down-regulation of these genes in ERAP2N-expressing TCs translates into a propensity for cell death. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that 64 DEGs were significantly enriched in nine pathways, including “Protein processing in endoplasmic reticulum” and “Antigen processing and presentation”, suggesting that the genes may be associated with peptide processes involved in immune recognition during the reproductive cycle.
- 10 August 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (16) , 8585
Open AccessOverexpression of ERAP2N in Human Trophoblast Cells Promotes Cell Death
The genes involved in implantation and placentation are tightly regulated to ensure a healthy pregnancy. The endoplasmic reticulum aminopeptidase 2 (ERAP2) gene is associated with preeclampsia (PE). Our studies have determined that an isoform of ERAP2-arginine (N), expressed in trophoblast cells (TC), significantly activates immune cells, and ERAP2N-expressing TCs are preferentially killed by both cytotoxic T lymphocytes (CTLs) and Natural Killer cells (NKCs). To understand the cause of this phenomenon, we surveyed differentially expressed genes (DEGs) between ERAP2N expressing and non-expressing TCs. Our RNAseq data revealed 581 total DEGs between the two groups. 289 genes were up-regulated, and 292 genes were down-regulated. Interestingly, most of the down-regulated genes of significance were pro-survival genes that play a crucial role in cell survival (LDHA, EGLN1, HLA-C, ITGB5, WNT7A, FN1). However, the down-regulation of these genes in ERAP2N-expressing TCs translates into a propensity for cell death. The Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that 64 DEGs were significantly enriched in nine pathways, including “Protein processing in endoplasmic reticulum” and “Antigen processing and presentation”, suggesting that the genes may be associated with peptide processes involved in immune recognition during the reproductive cycle.